CNDR Welcomes Dr. Hugh McMillan as New Pediatric Lead
Dr. Hugh McMillan
The Canadian Neuromuscular Disease Registry (CNDR) announced in February 2024 that Pediatric Lead Dr. Craig Campbell has decided to step down from his role, passing the torch to Dr. Hugh McMillan.
As the registry embarks on this transition, the CNDR warmly welcome Dr. McMillan as the new Pediatric Lead and are grateful for the wealth of knowledge, expertise, and leadership he will bring to the role.
Dr. Craig Campbell
National Principal Investigator Dr. Lawrence Korngut, CNDR investigators, and the CNDR National Office Team extend their heartfelt gratitude to Dr. Craig Campbell for his exceptional contributions and passionate support as co-founder and Pediatric Lead for the CNDR. Since the inception of the CNDR, Dr. Campbell has played a pivotal role, co-founding the registry in 2010. He has been integral to multiple disease working groups, including SMA, DMD, LGMD, DM, and CMS, offering invaluable guidance and expertise. As the CNDR’s Pediatric Lead Investigator, he has been instrumental in navigating the complex landscape of neuromuscular research, ensuring CNDR’s activities align with the evolving needs of their community. Dr Campbell, alongside Victoria Hodgkinson, also worked to integrate the CNDR within the global neuromuscular registry network of TREAT-NMD, and for 6 years led the global registry committee TGDOC, based largely on the strength and substantial contributions of the CNDR to the international efforts to make an impact for children and families living with neuromuscular diseases. Dr. Campbell’s passion and leadership have been catalysts in fostering collaboration and driving impactful outcomes for patients, and the CNDR are gratitude for his dedication and commitment.
Read next...
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.
New Best Practice Recommendations for SBMA Care in Canada
Congratulations to Dr. Kerri Schellenberg, the team of Canadian experts, NMD4C Steering Committee members and Investigators, on publishing the first Canadian SBMA care guidelines!
Advancing Neuromuscular Research and Care: Highlights from the 2025 NMD4C Annual Meeting
On September 11, NMD4C hosted its 2025 Annual Meeting in Ottawa, bringing together clinicians, researchers, trainees, and partners for a full day of collaboration, strategic dialogue, and community-building.
NMD4C Hosts Inaugural Clinical Summer School to Empower Canada’s Future Neuromuscular Leaders
On September 10–11, NMD4C hosted its inaugural Clinical Summer School in Ottawa, bringing together 19 neuromuscular clinical fellows from across Canada for two days of hands-on training, mentorship, and networking. Led by national experts and co-chaired by Drs. Gordon Jewitt and Marianne Nury, the program complemented NMD4C’s accredited lecture series and fostered peer connection through dedicated community-building sessions.
2026 Neuromuscular Postdoctoral Research Fellowships Funding Competition is Now Open!
Apply Or Share this opportunity with the trainees in your network — Deadline: October 14, 2025. Hosted by Neuromuscular Disease Network for Canada (NMD4C) and Muscular Dystrophy Canada (MDC)
Announcing the 2026 Neuromuscular Clinical Fellowship Award Recipients
We are excited to share that the 2026 Neuromuscular Clinical Fellowship Awards have been awarded! These fellowships strengthen clinical training in neuromuscular medicine and help prepare the next generation of specialists who will advance neuromuscular care across Canada.